Tempus AI (NASDAQ:TEM) Price Target Raised to $89.00

Tempus AI (NASDAQ:TEM) had its price objective boosted by Needham & Company LLC from $75.00 to $89.00 in a research note released on Monday, MarketBeat.com reports. Needham & Company LLC currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the company. Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Weiss Ratings raised Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. UBS Group initiated coverage on Tempus AI in a report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price target for the company. Rothschild & Co Redburn began coverage on Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $79.37.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $75.61 on Monday. The company’s 50 day simple moving average is $71.17 and its 200 day simple moving average is $57.20. The stock has a market capitalization of $13.64 billion, a price-to-earnings ratio of -71.33 and a beta of 3.61. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 3.16. Tempus AI has a 1 year low of $40.77 and a 1 year high of $89.09.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. During the same period in the previous year, the business earned ($0.46) earnings per share. The company’s revenue was up 23.1% on a year-over-year basis. As a group, research analysts predict that Tempus AI will post -1.45 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the sale, the executive vice president owned 146,067 shares in the company, valued at $7,246,383.87. This trade represents a 13.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the sale, the chief financial officer owned 106,024 shares in the company, valued at $6,361,440. This represents a 19.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,257,227 shares of company stock valued at $86,389,783 in the last quarter. 24.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TEM. Sumitomo Mitsui Trust Group Inc. increased its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. raised its stake in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Tempus AI by 2,965.7% during the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock valued at $41,233,000 after acquiring an additional 486,493 shares during the last quarter. Eagle Health Investments LP bought a new position in shares of Tempus AI during the first quarter valued at $11,588,000. Finally, Swiss National Bank lifted its holdings in shares of Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock worth $8,298,000 after purchasing an additional 600 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus reported third-quarter revenue of $411.5 million, up 23.1% year over year, and earnings of $0.07 per share—above expectations for a loss. The company also raised its 2026 revenue outlook to about $1.6 billion, citing oncology demand, data partnerships and potential reimbursement-driven pricing gains. Tempus Reports Third Quarter 2026 Results Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
• Positive Sentiment: Several analysts raised their price targets after the results: HC Wainwright to $85, and Baird and Cantor Fitzgerald to $92, with buy/outperform/overweight ratings. Analysts Boost Their Forecasts Following Strong Q3 Results
• Neutral Sentiment: The stock had climbed sharply following earnings, but one report argued it looked fully valued after its recent run. UBS maintained a Hold rating, citing solid oncology execution offset by weaker hereditary testing. Tempus AI Stock Looks Fully Priced Following Its Run UBS Hold Rating
• Negative Sentiment: The CEO and a director disclosed small stock sales, both conducted under pre-arranged Rule 10b5-1 plans. The limited size and planned nature make these sales a relatively weak signal, but they may add to near-term caution. SEC filing
• Negative Sentiment: Investors also face potential integration risks tied to Tempus AI’s proposed Personalis acquisition, which could add execution uncertainty. Personalis Acquisition Integration Risks

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.